Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Next Previous
X
Search
Trial Profile

Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitapivat (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Dec 2023 Results (at data cut off March 23, 2023) assessing the changes in the metabolome, lipidome and proteome of RBCs from patients with SCD presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (data cutoff March 23, 2023) evaluating the safety, tolerability and efficacy of mitapivat as a long-term maintenance therapy for pts with SCD, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 21 Apr 2023 Planned End Date changed from 19 Oct 2023 to 28 Feb 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top